psychedelics Archives

Every Psychedelic Company Is Racing to Get the Patient Out of the Chair Faster

Lilly paid up to $3.8 billion for a compound whose selling point is a two hour clinic visit. Session length, not efficacy, is now the axis that separates psychedelic programs.

Oregon Tracks Psilocybin Safety for Three Days. The New Data Found Problems at Three Months

A JAMA Network Open study followed 346 people through Oregon's licensed psilocybin program. The adverse events showed up long after the state stops looking.

The VA Just Started a Phase 3 Psilocybin Trial. The Control Group Gets Psilocybin Too

The VA began enrolling 240 veterans in a phase 3 psilocybin trial on August 3. There is no placebo arm, and that changes what the study can prove.

There Are Now Clinics for People Harmed by Psychedelics. Here Is Where They Are

Johns Hopkins opened the first US clinic for lasting psychedelic side effects. Where the clinics are, what they treat, what recovery looks like, and what to do meanwhile.

A Meditation Retreat Produced Psychedelic-Like Brain Changes. Here Is What the Study Actually Shows

A study is circulating with a striking claim. Seven days at a meditation retreat, no drugs involved, and participants’ brains showed connectivity patterns resembling those seen under psychedelics. The measurements are real. Nearly every headline about them is describing something the study did not do. New competition is a margin problem before it is a […]

An Oral LSD Tablet Has Now Cleared Phase 3 Twice This Year. Here Is What Comes Next

Editor’s note (September 16, 2026): DT120 has since cleared a third Phase 3 trial. We covered the Panorama results and the low-dose arm designed to address unblinding. An oral LSD tablet has now cleared phase 3 twice in a single year. Definium Therapeutics reported that DT120 ODT met its primary endpoint in generalized anxiety disorder, […]

MAPS-Funded MDMA Therapy for PTSD Is Back at the FDA, Without a New Phase 3 Trial

MDMA assisted therapy for PTSD appears to be back in front of the FDA. Psychedelic Alpha reported on August 9 that Resilient Pharmaceuticals has resubmitted the application the agency declined two years ago. MAPS responded to that report the next day without independently confirming it. The detail that matters is not the resubmission. It is […]

Every Psychedelic Company Is Racing to Get the Patient Out of the Chair Faster

Oregon Tracks Psilocybin Safety for Three Days. The New Data Found Problems at Three Months

The VA Just Started a Phase 3 Psilocybin Trial. The Control Group Gets Psilocybin Too

There Are Now Clinics for People Harmed by Psychedelics. Here Is Where They Are

A Meditation Retreat Produced Psychedelic-Like Brain Changes. Here Is What the Study Actually Shows

An Oral LSD Tablet Has Now Cleared Phase 3 Twice This Year. Here Is What Comes Next

MAPS-Funded MDMA Therapy for PTSD Is Back at the FDA, Without a New Phase 3 Trial

Psilocybin Sessions for PTSD Are Mostly Silent. The Argument About What to Call Them Is Not

Cluster Headaches Have New Trial Data. Ketamine Clinics Should Be Paying Attention

Ketamine Patients and GLP-1 Patients Are Often the Same People

Looking for Treatment?